NeoGenomics, Inc. (NEO)
| Market Cap | 1.20B +14.9% |
| Revenue (ttm) | 745.97M +10.9% |
| Net Income | -99.21M |
| EPS | -0.77 |
| Shares Out | 130.21M |
| PE Ratio | n/a |
| Forward PE | 38.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 779,058 |
| Open | 9.11 |
| Previous Close | 9.23 |
| Day's Range | 9.07 - 9.36 |
| 52-Week Range | 4.72 - 13.74 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 15.06 (+63.16%) |
| Earnings Date | Apr 28, 2026 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NEO stock is "Buy." The 12-month stock price target is $15.06, which is an increase of 63.16% from the latest price.
News
NeoGenomics Transcript: AGM 2026
The meeting covered board elections, executive compensation, equity plan amendments, and auditor ratification, with a quorum of 89.61% established. Voting results will be published in a Form 8-K, and no questions were raised during the Q&A.
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement...
Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo reta...
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in t...
NeoGenomics price target lowered to $11 from $13 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on NeoGenomics (NEO) to $11 from $13 and keeps a Neutral rating on the shares. 1 results were “modestly positive, though…
NeoGenomics price target raised to $14 from $13 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on NeoGenomics (NEO) to $14 from $13 and keeps a Buy rating on the shares. The firm said they reported…
Leerink upgrades NeoGenomics to Outperform, raises target to $25
As previously reported, Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a price target of $25, up from $12. The company delivers on its one-stop shop business model…
NeoGenomics upgraded to Buy from Hold at Benchmark
Benchmark upgraded NeoGenomics (NEO) to Buy from Hold with an $11 price target after the company reported better than expected revenue and in-line earnings and said it continues to plan…
NeoGenomics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a $25 price target
NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c
Reports Q1 reveneue $187M, consensus $184.48M. “The first quarter of 2026 was a truly transformational one for NeoGenomics (NEO). We again delivered double-digit revenue growth while making meaningful...
NeoGenomics raises FY26 revenue view to $797M-$803M from $793M-$801M
Consensus $796.63M. Backs FY26 adjusted EBITDA view $55M-$57M.
NeoGenomics Earnings Call Transcript: Q1 2026
Q1 2026 saw 11% revenue growth to $186.7M, led by 26% NGS growth and strong clinical demand. Guidance for 2026 was raised, with new product launches and reimbursement wins expected to drive further gains. Adjusted EBITDA rose 27% year-over-year.
NeoGenomics Earnings release: Q1 2026
NeoGenomics released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
NeoGenomics Slides: Q1 2026
NeoGenomics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
NeoGenomics Quarterly report: Q1 2026
NeoGenomics has published its Q1 2026 quarterly earnings report on April 28, 2026.
NeoGenomics Reports First Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.
NeoGenomics expands access to full oncology testing portfolio
NeoGenomics (NEO) announced that its oncology testing portfolio is now available through Epic Aura, enabling seamless access to oncologists and health systems across the United States through the Epic...
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' oncology testing portfolio is now available through Epic Aura.
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026.
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first qu...
NeoGenomics Proxy statement: Proxy filing
NeoGenomics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
NeoGenomics Proxy statement: Proxy filing
NeoGenomics filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
NeoGenomics PanTracer LBx test receives Medicare coverage
NeoGenomics (NEO) announced the PanTracer LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program under LCD – MolDX: Plasma-Based Genom...
NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
NeoGenomics Transcript: Leerink Global Healthcare Conference 2026
Leadership highlighted improved R&D-commercial alignment, operational gains, and a focus on profitable growth. Guidance calls for 9–10% revenue growth and margin expansion, driven by higher-value tests and sales force investments. Early uptake of PanTracer liquid and RaDaR ST is strong, with further growth expected as new products mature.